Cite

HARVARD Citation

    Nicolè, S. et al. (2018). Darunavir/ritonavir 600/100 mg once daily: it's time for larger non-inferiority randomized trials. Journal of antimicrobial chemotherapy. pp. 1728-1730. [Online]. 
  
Back to record